Back to search

Article

Ataluren Binds to Multiple Protein Synthesis Apparatus Sites and Competitively Inhibits Release Factor Dependent Termination

2022-03-23

Abstract excerpt

<title>Abstract</title> <p>Genetic diseases are often caused by nonsense mutations, but only one TRID (translation readthrough inducing drug), ataluren, has been approved for clinical use. Ataluren inhibits release factor complex (RFC) termination activity, while not affecting productive binding of near-cognate ternary complex (TC, aa-tRNA.eEF1A.GTP). Here we use photoaffinity labeling to identify two sites of at...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
614f4e08-d526-54d0-a11b-7bca4995f547
DOI
10.21203/rs.3.rs-1451662/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Ataluren Binds to Multiple Protein Synthesis Apparatus Sites and Competitively Inhibits Release Factor Dependent TerminationDOI 10.21203/rs.3.rs-1451662/v1
Select a neighboring publication to make it the new centre.